Calabresi
Francis J. Calabresi, Harvard, MA US
Patent application number | Description | Published |
---|---|---|
20090274471 | METHOD AND APPARATUS FOR CONTROLLING THE OPTICAL OUTPUT POWER FROM A BURST MODE LASER - An optical network terminal is provided for use in a passive optical network (PON). The optical network terminal includes a data port for receiving data packets from an external device and a processor for converting the data packets to data link frames. In addition, the optical network terminal includes a memory configured to store a time division multiplexing scheme identifying a time slot assigned to each of a plurality of network nodes in the PON for transmission of upstream optical signals. An optical transceiver is provided for converting the data link frames to upstream optical signals and transmitting the optical signals on an upstream TDMA (time division, multiple access) channel to an Optical Line Terminal (OLT). The optical transceiver includes a burst mode laser diode for generating the optical signals and a burst mode laser driver for biasing the laser diode with a bias signal and a modulation bias signal. The laser driver includes a dual closed loop feedback control circuit. The dual closed loop feedback control circuit is configured to measure and adjust a logic zero output power level from the laser diode during a time slot identified from the time division multiplexing scheme stored in the memory. | 11-05-2009 |
20090310961 | METHOD AND APPARATUS FOR CALIBRATING BURST MODE LASER TRANSMITTERS - A method is provided to calibrate a monitor photodiode that measures the optical output power generated by an optoelectronic transceiver module that includes a burst mode laser diode. The method includes disabling the power control loop that controls an average optical output power generated by the laser diode during a laser burst. A series of logic zero signals is applied to a data input of the transceiver module and the logic zero level of the optical signal generated by the burst mode laser diode while applying the series of logic zero signals is measured. The logic zero bias level applied to the laser diode is adjusted until the measured logic zero level of the optical signal reaches a first desired value. While maintaining the optical signal at the first desired value, a first value of a current generated by the monitor photodiode in response to optical energy received from a back facet of the laser diode is stored. The first value of the current represents the calibrated value of the monitor current that will be measured when the laser generates a proper logic zero optical signal. | 12-17-2009 |
20090315626 | High Sensitivity Optical Receiver Employing a High Gain Amplifier and an Equalizing Circuit - An optical receiver includes a light receiving element for converting an optical signal to an electrical signal having a first bandwidth and an amplifier for amplifying the electrical signal. The amplifier has a first gain response that yields a second bandwidth that is less than the first bandwidth. The optical receiver also includes an equalizing circuit operationally coupled to the amplifier. The equalizing circuit has a second gain response that compensates for the first gain response of the amplifier so that a substantially constant net gain is imparted by the amplifier and the equalizing circuit to the electrical signal over the first bandwidth. | 12-24-2009 |
Marcello Calabresi, Cardano IT
Patent application number | Description | Published |
---|---|---|
20100267835 | Methods of treating disorders of trigeminalvascular activation - Alpha-aminoamide derivatives useful in the treatment of disorders of trigeminalvascular activation are disclosed. | 10-21-2010 |
Paolo Calabresi, Perugia IT
Patent application number | Description | Published |
---|---|---|
20130183278 | METHOD FOR DIAGNOSIS - The present invention relates to method of identifying whether or not an individual has Parkinson's disease (PD). In particular, the invention relates to a method for identifying whether or not an individual has PD as opposed to another neurodegenerative disease. The method of the invention comprises measuring the concentration of α-synuclein (α-syn) and the concentration of unphosphorylated tau (tau) and/or phosphorylated tau (p-tau) in a cerebrospinal fluid sample taken from an individual. The method also comprises calculating the ratio of the concentration of tau and/or p-tau to the concentration of α-syn, and thereby determining whether or not the individual has PD. | 07-18-2013 |
Paul Calabresi, Barrington, RI US
Patent application number | Description | Published |
---|---|---|
20090163479 | USE OF TAUROLIDINE TO TREAT TUMORS - The invention provides a method of inhibiting tumor growth in a mammal, by administering to the mammal composition containing taurolidine, taurultam, or a biologically active derivative thereof. The composition is administered to directly contact a tumor cell at a dose sufficient to induce cell death by apoptosis. | 06-25-2009 |
Peter Calabresi, Lutherville, MD US
Patent application number | Description | Published |
---|---|---|
20100239562 | Kv CHANNELS IN NEURODEGENERATION AND NEUROPROTECTION - A family of potassium channels (Kv) are expressed in neurons when they are damaged. Blockers of these channels protect neurons from several different types of insults, whether due to disease or trauma. Furthermore, blockers of these channels promote neurite outgrowth in neural progenitor cells. These findings permit methods of treating as well as methods for identifying and developing drugs for neurological diseases where injury to neurons may occur. | 09-23-2010 |
Peter Arthur Calabresi, Lutherville, MD US
Patent application number | Description | Published |
---|---|---|
20110123482 | Methods of Treating Neurological Autoimmune Disorders with Cyclophosphamide - Described herein are methods for treating neurological autoimmune disorders in which the treatment method includes administering an immunoablative agent to eliminate most or essentially all maturing and mature elements of the immune system in an affected individual. Following this step, the individual is administered agents to reestablish the ablated immune system. | 05-26-2011 |